Related Experiment Video
Updated: Apr 5, 2026
Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells
Published on: June 13, 2018
Validation of the Lower-Risk MD Anderson Prognostic Scoring System for Patients With Myelodysplastic Syndrome
Rami Komrokji1, Hanadi Ramadan1, Najla Al Ali1
1H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
Abstract:
The International Prognostic Scoring System (IPSS) is the most widely used tool for risk assessment and treatment decisions for myelodysplastic syndrome (MDS). Several new models have been proposed to identify a subset of lower-risk patients with MDS who are experiencing inferior than expected outcomes. We validated the Lower-Risk MD Anderson Risk Model (LR-MDAS) in 1288 lower-risk patients with MDS by the IPSS. On the basis of the LR-MDAS, 228 patients (17%) were in category 1, 730 patients (57%) were in category 2, 315 patients (25%) were in category 3, and 15 patients (1%) were in an unknown category. The median overall survival for the corresponding LR-MDAS categories was (1) 109 months (95% confidence interval [CI], 82-137), (2) 56 months (95% CI, 58-73), and (3) 29 months (95% CI, 24-35) (P < .005). Overall, 25% of patients were upstaged to category 3. LR-MDAS refined prognostic value among very low-, low-, and intermediate-risk Revised IPSS. The rate of acute myeloid leukemia transformation according to LR-MDAS was 15%, 18%, and 29% for categories 1, 2, and 3, respectively (P < .005). Our data validate the prognostic value of the LR-MDAS model, but the utility of it as a treatment decision tool should be studied prospectively.
Insights
The Lower-Risk MD Anderson Risk Model (LR-MDAS) effectively refines risk stratification for myelodysplastic syndrome (MDS) patients. This model improves upon the International Prognostic Scoring System (IPSS) by identifying lower-risk MDS patients with poorer prognoses.
Area of Science:
- Hematology
- Oncology
- Medical Statistics
Background:
- The International Prognostic Scoring System (IPSS) is standard for myelodysplastic syndrome (MDS) risk assessment.
- New models are needed to identify lower-risk MDS patients with unexpectedly poor outcomes.
- The Lower-Risk MD Anderson Risk Model (LR-MDAS) was developed to address this need.
Purpose of the Study:
- To validate the prognostic accuracy of the LR-MDAS in a large cohort of lower-risk MDS patients.
- To compare the LR-MDAS with the existing IPSS for risk stratification.
- To assess the LR-MDAS's ability to predict overall survival and acute myeloid leukemia transformation.
Main Methods:
- Retrospective validation of the LR-MDAS model in 1288 lower-risk MDS patients previously assessed by IPSS.
- Categorization of patients into LR-MDAS risk groups (1, 2, 3).
- Analysis of overall survival and acute myeloid leukemia transformation rates across LR-MDAS categories.
Main Results:
- LR-MDAS categorized patients into three distinct risk groups with significantly different median overall survival (109, 56, and 29 months).
- The model identified 25% of patients as higher risk than initially assessed by IPSS.
- Acute myeloid leukemia transformation rates increased across LR-MDAS categories (15%, 18%, 29%).
Conclusions:
- The LR-MDAS model demonstrates significant prognostic value in refining risk stratification for lower-risk MDS patients.
- LR-MDAS improves upon the IPSS by identifying a subset of patients with inferior prognoses.
- Prospective studies are warranted to evaluate the LR-MDAS as a clinical treatment decision tool.
More Related Videos
08:18Multiplexed Barcoding Image Analysis for Immunoprofiling and Spatial Mapping Characterization in the Single-Cell Analysis of Paraffin Tissue Samples
Published on: April 7, 2023
08:01Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
Published on: April 21, 2022